Anti-malarial compositions
View Patent ↗This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.
1. An isolated antibody which:
(a) comprises:
(1) an immunoglobulin heavy chain variable region, comprising a first heavy chain complementarity determining region (CDR H ) comprising the amino acid sequence SEQ ID NO:1; a second CDR H comprising the amino acid sequence SEQ ID NO:2; and a third CDR H comprising the amino acid sequence SEQ ID NO:3; and
(2) an immunoglobulin light chain variable region comprising a first light chain complementarity determining region (CDR L ) comprising the amino acid sequence SEQ ID NO:4; a second CDR L comprising the amino acid sequence SEQ ID NO:5; and a third CDR L comprising the amino acid sequence SEQ ID NO:6;
or
(b) comprises the complementarity determining regions of the immunoglobulin heavy and light chains of the antibody deposited under Accession No. MRA-1242.
2. The isolated antibody of claim 1 , which is an scFv antibody.
3. The isolated antibody of claim 1 , which is humanized.
4. A pharmaceutical composition, comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
5. A method of protecting an individual against a Plasmodium infection, comprising administering to an individual in need thereof an effective amount of a pharmaceutical composition comprising the antibody of claim 1 .
6. The method of claim 5 , further comprising administering to the individual a malarial antigen.
7. A method of treating malaria, comprising administering to an individual in need thereof an effective amount of a pharmaceutical composition comprising the antibody of claim 1 .
8. The method of claim 7 , further comprising administering to the individual an anti-malarial drug.
9. The antibody deposited under Accession No. MRA-1242.
10. The isolated antibody of claim 1 , which comprises:
(1) the immunoglobulin heavy chain variable region, comprising the first heavy chain complementarity determining region (CDR H ) comprising the amino acid sequence SEQ ID NO:1; the second CDR H comprising the amino acid sequence SEQ ID NO:2; and the third CDR H comprising the amino acid sequence SEQ ID NO:3; and
(2) the immunoglobulin light chain variable region comprising the first light chain complementarity determining region (CDR L ) comprising the amino acid sequence SEQ ID NO:4; the second CDR L comprising the amino acid sequence SEQ ID NO:5; and the third CDR L comprising the amino acid sequence SEQ ID NO:6.
11. The isolated antibody of claim 10 , which is an scFv antibody.
12. The isolated antibody of claim 10 , which is humanized.
13. The isolated antibody of claim 1 , which comprises the complementarity determining regions of the immunoglobulin heavy and light chains of the antibody deposited under Accession No. MRA-1242.
14. The isolated antibody of claim 13 , which is an scFv antibody.
15. The isolated antibody of claim 13 , which is humanized.
16. The pharmaceutical composition of claim 4 , wherein the isolated antibody comprises:
(1) the immunoglobulin heavy chain variable region, comprising the first heavy chain complementarity determining region (CDR H ) comprising the amino acid sequence SEQ ID NO:1; the second CDR H comprising the amino acid sequence SEQ ID NO:2; and the third CDR H comprising the amino acid sequence SEQ ID NO:3; and
(2) the immunoglobulin light chain variable region comprising the first light chain complementarity determining region (CDR L ) comprising the amino acid sequence SEQ ID NO:4; the second CDR L comprising the amino acid sequence SEQ ID NO:5; and the third CDR L comprising the amino acid sequence SEQ ID NO:6.
17. The pharmaceutical composition of claim 16 , wherein the isolated antibody is an scFv antibody.
18. The pharmaceutical composition of claim 16 , wherein the isolated antibody humanized.
19. The pharmaceutical composition of claim 4 , wherein the isolated antibody comprises the complementarity determining regions of the immunoglobulin heavy and light chains of the antibody deposited under Accession No. MRA-1242.
20. The pharmaceutical composition of claim 19 , wherein the isolated antibody is an scFv antibody.
21. The pharmaceutical composition of claim 19 , wherein the isolated antibody is humanized.
22. A pharmaceutical composition comprising the antibody deposited under Accession No. MRA-1242 and a pharmaceutically acceptable carrier.